Cargando…

Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions

Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Economopoulou, Panagiota, Pantazopoulos, Anastasios, Spathis, Aris, Kotsantis, Ioannis, Kyriazoglou, Anastasios, Kavourakis, George, Zakopoulou, Roubini, Chatzidakis, Ioannis, Anastasiou, Maria, Prevezanou, Maria, Resteghini, Carlo, Licitra, Lisa, Bergamini, Cristiana, Colombo, Elena, Caspani, Francesca, Denaro, Nerina, Vecchio, Stefania, Bonomo, Pierluigi, Cossu Rocca, Maria, Bertolini, Federica, Ferrari, Daris, Psyrri, Amanda, Bossi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750043/
https://www.ncbi.nlm.nih.gov/pubmed/35011594
http://dx.doi.org/10.3390/cells11010032
_version_ 1784631371081187328
author Economopoulou, Panagiota
Pantazopoulos, Anastasios
Spathis, Aris
Kotsantis, Ioannis
Kyriazoglou, Anastasios
Kavourakis, George
Zakopoulou, Roubini
Chatzidakis, Ioannis
Anastasiou, Maria
Prevezanou, Maria
Resteghini, Carlo
Licitra, Lisa
Bergamini, Cristiana
Colombo, Elena
Caspani, Francesca
Denaro, Nerina
Vecchio, Stefania
Bonomo, Pierluigi
Cossu Rocca, Maria
Bertolini, Federica
Ferrari, Daris
Psyrri, Amanda
Bossi, Paolo
author_facet Economopoulou, Panagiota
Pantazopoulos, Anastasios
Spathis, Aris
Kotsantis, Ioannis
Kyriazoglou, Anastasios
Kavourakis, George
Zakopoulou, Roubini
Chatzidakis, Ioannis
Anastasiou, Maria
Prevezanou, Maria
Resteghini, Carlo
Licitra, Lisa
Bergamini, Cristiana
Colombo, Elena
Caspani, Francesca
Denaro, Nerina
Vecchio, Stefania
Bonomo, Pierluigi
Cossu Rocca, Maria
Bertolini, Federica
Ferrari, Daris
Psyrri, Amanda
Bossi, Paolo
author_sort Economopoulou, Panagiota
collection PubMed
description Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature. Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049). Safety was manageable. Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI.
format Online
Article
Text
id pubmed-8750043
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87500432022-01-12 Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions Economopoulou, Panagiota Pantazopoulos, Anastasios Spathis, Aris Kotsantis, Ioannis Kyriazoglou, Anastasios Kavourakis, George Zakopoulou, Roubini Chatzidakis, Ioannis Anastasiou, Maria Prevezanou, Maria Resteghini, Carlo Licitra, Lisa Bergamini, Cristiana Colombo, Elena Caspani, Francesca Denaro, Nerina Vecchio, Stefania Bonomo, Pierluigi Cossu Rocca, Maria Bertolini, Federica Ferrari, Daris Psyrri, Amanda Bossi, Paolo Cells Article Background: nasopharyngeal carcinoma (NPC) is a complex disease entity that mainly predominates in endemic regions. Real-world data with immunotherapy from nonendemic regions are limited. Methods: we collected data from patients with recurrent/metastatic (R/M) NPC treated at a center in Greece and 8 centers in Italy. Between 2016 and 2021, 46 patients who were treated with at least one cycle of immune checkpoint inhibitors (ICI) were identified. Herein, we present our results and a review of the literature. Results: assessment of response was available in 42 patients. Overall, 11 patients responded to immunotherapy (Overall Response Rate-ORR 26.2%). Three patients had complete response (CR), and 8 patients had partial response (PR). Disease control rate (DCR) was 61.9%. Median Progression Free Survival (PFS) was 5.6 months and median Overall Survival (OS) was 19.1 months. Responders to ICI improved PFS and OS as compared to that of nonresponders. A lower probability of responding to ICI was shown in patients with more than three metastatic sites (p = 0.073), metastatic disease at initial diagnosis, (p = 0.039) or EBV DNA positive before ICI initiation, (p = 0.074). Decline in EBV DNA levels was found to be statistically significant associated with best response to ICI (p = 0.049). Safety was manageable. Conclusions: among 46 patients with R/M NPC treated with immunotherapy in two nonendemic regions, ORR was 26.2% and durable responses were observed. Low disease burden could serve as a biomarker for response to ICI. MDPI 2021-12-23 /pmc/articles/PMC8750043/ /pubmed/35011594 http://dx.doi.org/10.3390/cells11010032 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Economopoulou, Panagiota
Pantazopoulos, Anastasios
Spathis, Aris
Kotsantis, Ioannis
Kyriazoglou, Anastasios
Kavourakis, George
Zakopoulou, Roubini
Chatzidakis, Ioannis
Anastasiou, Maria
Prevezanou, Maria
Resteghini, Carlo
Licitra, Lisa
Bergamini, Cristiana
Colombo, Elena
Caspani, Francesca
Denaro, Nerina
Vecchio, Stefania
Bonomo, Pierluigi
Cossu Rocca, Maria
Bertolini, Federica
Ferrari, Daris
Psyrri, Amanda
Bossi, Paolo
Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions
title Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions
title_full Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions
title_fullStr Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions
title_full_unstemmed Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions
title_short Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic Regions
title_sort immunotherapy in nonendemic nasopharyngeal carcinoma: real-world data from two nonendemic regions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750043/
https://www.ncbi.nlm.nih.gov/pubmed/35011594
http://dx.doi.org/10.3390/cells11010032
work_keys_str_mv AT economopouloupanagiota immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT pantazopoulosanastasios immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT spathisaris immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT kotsantisioannis immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT kyriazoglouanastasios immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT kavourakisgeorge immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT zakopoulouroubini immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT chatzidakisioannis immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT anastasioumaria immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT prevezanoumaria immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT resteghinicarlo immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT licitralisa immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT bergaminicristiana immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT colomboelena immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT caspanifrancesca immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT denaronerina immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT vecchiostefania immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT bonomopierluigi immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT cossuroccamaria immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT bertolinifederica immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT ferraridaris immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT psyrriamanda immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions
AT bossipaolo immunotherapyinnonendemicnasopharyngealcarcinomarealworlddatafromtwononendemicregions